Monopar Historical Financial Ratios
| MNPR Stock | USD 20.10 0.39 1.98% |
Monopar Therapeutics is lately reporting on over 79 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Monopar Therapeutics financial condition quickly.
Monopar |
About Monopar Financial Ratios Analysis
Monopar TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Monopar Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Monopar financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Monopar Therapeutics history.
Monopar Therapeutics Financial Ratios Chart
Add Fundamental
Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from Monopar Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.At this time, Monopar Therapeutics' Interest Debt Per Share is relatively stable compared to the past year. As of 11/25/2024, Price Earnings To Growth Ratio is likely to grow to 0.10, though Free Cash Flow Yield is likely to grow to (0.30).
Monopar Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Monopar Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Monopar Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 69.59 | 21.37 | 10.57 | 14.94 | 4.41 | 4.19 | |
| Book Value Per Share | 0.66 | 1.19 | 1.43 | 1.52 | 0.79 | 0.39 | |
| Free Cash Flow Yield | (0.003434) | (0.0139) | (0.0366) | (0.048) | (0.32) | (0.3) | |
| Operating Cash Flow Per Share | (0.28) | (0.29) | (0.43) | (0.59) | (0.57) | (0.54) | |
| Pb Ratio | 69.59 | 21.37 | 10.57 | 14.94 | 4.41 | 4.19 | |
| Free Cash Flow Per Share | (0.28) | (0.29) | (0.43) | (0.59) | (0.57) | (0.54) | |
| Roic | (0.48) | (0.33) | (0.41) | (1.04) | (1.58) | (1.5) | |
| Net Income Per Share | (0.39) | (0.57) | (0.73) | (0.83) | (0.58) | (0.61) | |
| Cash Per Share | 1.25 | 1.53 | 1.63 | 1.03 | 0.5 | 0.7 | |
| Pocfratio | (291.21) | (71.92) | (27.36) | (20.85) | (3.14) | (3.3) | |
| Pfcf Ratio | (291.21) | (71.92) | (27.36) | (20.85) | (3.14) | (3.3) | |
| Income Quality | 0.71 | 0.74 | 0.8 | 0.69 | 0.94 | 0.61 | |
| Roe | (0.33) | (0.4) | (0.48) | (1.04) | (1.5) | (1.58) | |
| Ev To Operating Cash Flow | (286.83) | (68.33) | (24.58) | (19.72) | (2.21) | (2.33) | |
| Pe Ratio | (212.99) | (53.89) | (22.05) | (14.36) | (2.94) | (3.08) | |
| Return On Tangible Assets | (0.44) | (0.31) | (0.37) | (0.79) | (1.14) | (1.2) | |
| Ev To Free Cash Flow | (286.83) | (68.33) | (24.58) | (19.72) | (2.21) | (2.33) | |
| Earnings Yield | (0.004695) | (0.0186) | (0.0454) | (0.0696) | (0.34) | (0.32) | |
| Current Ratio | 18.27 | 14.28 | 12.98 | 4.21 | 4.17 | 3.96 | |
| Tangible Book Value Per Share | 0.66 | 1.19 | 1.43 | 1.52 | 0.79 | 0.39 | |
| Graham Number | 3.23 | 4.28 | 4.99 | 3.84 | 2.24 | 2.48 | |
| Shareholders Equity Per Share | 0.66 | 1.19 | 1.43 | 1.52 | 0.79 | 0.39 | |
| Graham Net Net | 1.18 | 1.42 | 1.5 | 0.78 | 0.38 | 0.63 | |
| Price Earnings Ratio | (212.99) | (53.89) | (22.05) | (14.36) | (2.94) | (3.08) | |
| Price Book Value Ratio | 69.59 | 21.37 | 10.57 | 14.94 | 4.41 | 4.19 | |
| Price Earnings To Growth Ratio | (8.25) | (1.17) | (0.79) | (1.05) | 0.0975 | 0.1 | |
| Price To Operating Cash Flows Ratio | (291.21) | (71.92) | (27.36) | (20.85) | (3.14) | (3.3) | |
| Price To Free Cash Flows Ratio | (291.21) | (71.92) | (27.36) | (20.85) | (3.14) | (3.3) | |
| Effective Tax Rate | 0.0234 | 0.013 | 0.002639 | 0.00202 | 0.002323 | 0.002207 | |
| Return On Capital Employed | (0.34) | (0.41) | (0.48) | (1.04) | (1.58) | (1.66) | |
| Quick Ratio | 18.27 | 14.28 | 12.98 | 4.21 | 4.17 | 3.96 | |
| Cash Ratio | 18.25 | 14.22 | 12.85 | 2.62 | 4.13 | 3.93 |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Monopar Stock
| 0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | AGL | agilon health Buyout Trend | PairCorr |
| 0.81 | NKTX | Nkarta Inc | PairCorr |
| 0.79 | MTEM | Molecular Templates | PairCorr |
| 0.78 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.